A phase II study combining the PPARγ agonist pioglitazone and rofecoxib with low-dose chemotherapy in high-grade gliomas pointed out a moderate benefit and encourages the future use of this cocktail in highly selected patients [168]. Here, PPARG is linked to central nervous system cancer.